Skip to main content
Raavi Gupta, MD, Pathology, Brooklyn, NY, SUNY Downstate Health Sciences University

RaaviGuptaMD

Pathology Brooklyn, NY

Hematopathology, Anatomic Pathology, Clinical Pathology

Professor, Pathology, SUNY-Downstate College of Medicine

Dr. Gupta is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Gupta's full profile

Already have an account?

Education & Training

  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Pathology-Anatomic and Clinical, 2007 - 2008
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematopathology, 2006 - 2007
  • UMMS-Baystate
    UMMS-BaystateResidency, Pathology-Anatomic and Clinical, 2002 - 2006
  • King George's/CSM Medical College
    King George's/CSM Medical CollegeClass of 1998

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2008 - 2026
  • VA State Medical License
    VA State Medical License 2012 - 2024
  • MA State Medical License
    MA State Medical License 2006 - 2009
  • American Board of Pathology Pathology - Anatomic/Pathology - Clinical
  • American Board of Pathology Hematopathology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Case Report: Monoclonal Gammopathy of Undetermined Significance Is Associated with Loa Loa Infection  
    Raavi Gupta, Herbert B Tanowitz, Derek B Laskar, The American Journal of Tropical Medicine and Hygiene

Press Mentions

  • Histogen and Amerimmune Report Publication on Emricasan in COVID-19
    Histogen and Amerimmune Report Publication on Emricasan in COVID-19May 19th, 2021
  • Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients
    Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic COVID-19 PatientsMarch 16th, 2021

Hospital Affiliations